<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00083382</url>
  </required_header>
  <id_info>
    <org_study_id>UARK 98-036</org_study_id>
    <nct_id>NCT00083382</nct_id>
  </id_info>
  <brief_title>Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide</brief_title>
  <official_title>UARK 98-036, A Phase II Trial of Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide in Patients With Smoldering/Indolent Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Arkansas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to study how helpful the combination of thalidomide and
      Pamidronate or thalidomide and Zometa is in controlling the myeloma disease and to study any
      side effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recently laboratory research found that thalidomide can inhibit the formation of new blood
      vessels that are necessary for the growth and spread of cancer. In order to grow and increase
      in size tumors require new blood vessels to supply them with the necessary blood to grow. If
      we can prevent these new blood vessels feeding the tumor from being formed by using
      thalidomide we might slow or stop the growth of the tumor. This concept is called
      &quot;anti-angiogenesis&quot; It is hoped that thalidomide will slow or stop the growth myeloma.
      However, it cannot be guaranteed that you will benefit if you take part in this study. The
      treatment you receive may even be harmful.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1998</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best Response</measure>
    <time_frame>2 years</time_frame>
    <description>Best response to study treatment as defined by protocol-specific response criteria:
Complete Response (CR) = absence of urine and serum M-components by immunofixation; bone marrow should be adequately cellular (&gt;20%) with &lt;1% monoclonal plasma cells by DNA-clg flow cytometry; serum calcium level must be normal; no new bone lesions nor enlargement of existing lesions; Normalization of serum concentrations of normal immunoglobulins is not required for CR. Partial Response (PR) = Reduction by &gt; 75% in serum myeloma protein production; Decrease in monoclonal marrow plasmacytosis to &lt;5%; Decrease in Bence-Jones proteinuria by &gt;90%; No new lytic bone lesions or soft tissue plasmacytoma.
Treatment Failures/Progressive Disease (PD) = Such patients do not fulfill the above criteria and/or have new lytic lesions (but not compression fractures), hypercalcemia, or other new manifestations of disease.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">83</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Thalidomide + Bisphosphonate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg/day Thalidomide + 90 mg Pamidronate OR 4 mg Zometa every 2 weeks for 2 months and then every 4 weeks as maintenance therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pamidronate</intervention_name>
    <description>Patients will receive either pamidronate or zometa. Pamidronate is administered at a dose of 90 mg by continuous infusion over 90 minutes, every two weeks for 2 months. Disease will be reassessed after two cycles. Those with stable disease or better will receive 90 mg every 4 weeks as maintenance therapy.</description>
    <arm_group_label>Thalidomide + Bisphosphonate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide</intervention_name>
    <description>All Patients will receive thalidomide 200 mg as an oral, once daily dose. Dose may be reduced to as low as 50 mg qod in the event of severe toxicity. Thalidomide will continue daily as tolerated until criteria to remove from study are met.
Patients will receive appropriate regimen to prevent constipation (i.e., colace, dulcolax, milk of magnesia, or lactulose)</description>
    <arm_group_label>Thalidomide + Bisphosphonate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zometa</intervention_name>
    <description>Patients will receive either pamidronate or zometa. Zometa is administered at a dose of 4 mg by continuous infusion every two weeks for 2 months. Disease will be reassessed after two cycles. Those with stable disease or better will receive 4 mg every 4 weeks as maintenance therapy.</description>
    <arm_group_label>Thalidomide + Bisphosphonate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have a diagnosis of Smoldering or Indolent myeloma

          -  All patients must be informed of the investigational nature of this study and must
             sign a written informed consent in accordance with UAMS Human Research Advisory
             Committee and federal guidelines.

        Exclusion Criteria:

          -  Prior bisphosphonate therapy within 30 days prior to study entry.

          -  Serum creatinine &gt; 5 mg/dl, ascites, or serum direct bilirubin &gt; 2.5 mg/dl.

          -  Prior plicamycin or calcitonin within 2 weeks of study entry.

          -  Severe cardiac disease, unstable thyroid disease, or epilepsy.

          -  Prior radiation therapy to &gt; 20% of the skeleton.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bart Barlogie, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arkansas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences/MIRT</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://myeloma.uams.edu</url>
    <description>Myeloma Institute for Research &amp; Therapy</description>
  </link>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2004</study_first_submitted>
  <study_first_submitted_qc>May 21, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2004</study_first_posted>
  <results_first_submitted>June 5, 2015</results_first_submitted>
  <results_first_submitted_qc>June 5, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 24, 2015</results_first_posted>
  <last_update_submitted>June 5, 2015</last_update_submitted>
  <last_update_submitted_qc>June 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myeloma</keyword>
  <keyword>Thalidomide</keyword>
  <keyword>Pamidronate</keyword>
  <keyword>Aredia</keyword>
  <keyword>Bisphosphonate</keyword>
  <keyword>Anti-Angiogenesis</keyword>
  <keyword>Smoldering/Indolent Myeloma</keyword>
  <keyword>Zometa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Zoledronic acid</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Thalidomide + Bisphosphonate</title>
          <description>200 mg/day Thalidomide + 90 mg Pamidronate OR 4 mg Zometa every 2 weeks for 2 months and then every 4 weeks as maintenance therapy
Thalidomide: All Patients will receive thalidomide 200 mg as an oral once daily dose. Dose may be reduced to as low as 50 mg qod in the event of severe toxicity. Thalidomide will continue daily as tolerated until criteria to remove from study are met. Patients will receive appropriate regimen to prevent constipation (i.e., colace, dulcolax, milk of magnesia, or lactulose)
Pamidronate: Patients will receive either pamidronate or zometa. Pamidronate is administered at a dose of 90 mg by continuous infusion over 90 minutes, every two weeks for 2 months. Disease will be reassessed after two cycles. Those with stable disease or better will receive 90 mg every 4 weeks as maintenance therapy.
Zometa: Patients will receive either pamidronate or zometa. Zometa is administered at a dose of 4 mg by continuous infusion every two weeks for 2 months. Dise</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="83"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="83"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Thalidomide + Bisphosphonate</title>
          <description>200 mg/day Thalidomide + 90 mg Pamidronate OR 4 mg Zometa every 2 weeks for 2 months and then every 4 weeks as maintenance therapy</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="83"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.0" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Best Response</title>
        <description>Best response to study treatment as defined by protocol-specific response criteria:
Complete Response (CR) = absence of urine and serum M-components by immunofixation; bone marrow should be adequately cellular (&gt;20%) with &lt;1% monoclonal plasma cells by DNA-clg flow cytometry; serum calcium level must be normal; no new bone lesions nor enlargement of existing lesions; Normalization of serum concentrations of normal immunoglobulins is not required for CR. Partial Response (PR) = Reduction by &gt; 75% in serum myeloma protein production; Decrease in monoclonal marrow plasmacytosis to &lt;5%; Decrease in Bence-Jones proteinuria by &gt;90%; No new lytic bone lesions or soft tissue plasmacytoma.
Treatment Failures/Progressive Disease (PD) = Such patients do not fulfill the above criteria and/or have new lytic lesions (but not compression fractures), hypercalcemia, or other new manifestations of disease.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Thalidomide + Bisphosphonate</title>
            <description>200 mg/day Thalidomide + 90 mg Pamidronate OR 4 mg Zometa every 2 weeks for 2 months and then every 4 weeks as maintenance therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Best Response</title>
          <description>Best response to study treatment as defined by protocol-specific response criteria:
Complete Response (CR) = absence of urine and serum M-components by immunofixation; bone marrow should be adequately cellular (&gt;20%) with &lt;1% monoclonal plasma cells by DNA-clg flow cytometry; serum calcium level must be normal; no new bone lesions nor enlargement of existing lesions; Normalization of serum concentrations of normal immunoglobulins is not required for CR. Partial Response (PR) = Reduction by &gt; 75% in serum myeloma protein production; Decrease in monoclonal marrow plasmacytosis to &lt;5%; Decrease in Bence-Jones proteinuria by &gt;90%; No new lytic bone lesions or soft tissue plasmacytoma.
Treatment Failures/Progressive Disease (PD) = Such patients do not fulfill the above criteria and/or have new lytic lesions (but not compression fractures), hypercalcemia, or other new manifestations of disease.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment Failure/Progressive Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Thalidomide + Bisphosphonate</title>
          <description>200 mg/day Thalidomide + 90 mg Pamidronate OR 4 mg Zometa every 2 weeks for 2 months and then every 4 weeks as maintenance therapy</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular-other</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea without colostomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>GI-other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue/malaise/lethargy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Speech impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint, muscle, bone-other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonitis/infiltrates</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Lung-other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Respiratory infect w/o neutrop</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 1 Anemia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 2 Anemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 1 Neutropenia/granulocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 2 Neutropenia/granulocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 1 Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 2 Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 3 Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 2 Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 1 Arrhythmia, NOS</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 4 Cardiovascular - other</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 1 Edema</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 2 Edema</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 1 Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 2 Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 1 Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 2 Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 2 Blurred vision</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 1 Eye - other</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 1 Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 2 Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 2 Constipation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 1 Constipation/bowel obstruction</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 2 Constipation/bowel obstruction</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 3 Constipation/bowel obstruction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 1 Diarrhea without colostomy</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 2 Diarrhea without colostomy</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 1 GI - other</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 1 Mouth dryness</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 2 Mouth dryness</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 1 Nausea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 2 Nausea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 1 Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 1 Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 2 Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 3 Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 1 Fever without neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 2 Fever without neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 1 Fever, NOS</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 2 Fever, NOS</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 2 Sweating</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 1 weight gain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 2 weight gain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 1 weight loss</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 1 Headache</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 2 Headache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 1 Somnolence/consciousness loss</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 2 Somnolence/consciousness loss</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 3 Somnolence/consciousness loss</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 1 Bone Pain</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 2 Bone Pain</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 3 Bone Pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 1 Chest pain, not cardio or pleural</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 2 Lower Back</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 1 Pain - other</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 2 Pain - other</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 3 Pain - other</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 1 Upper Back</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 1 Alkaline phosphatase increase</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 1 Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 2 Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 1 SGOT (AST) increase</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 1 SGPT (ALT) increase</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 1 Allergic rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Grade 1 Infection w/o 3-4 neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 2 Infection w/o 3-4 neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 2 Respiratory infect w/o neutrop</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 1 Bicarbonate decrease</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 1 Hypercalcemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 1 Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 2 Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 3 Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 1 Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 2 Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 1 Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 1 Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 1 Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 3 Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 2 Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 3 Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 2 Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 1 Joint, muscle, bone - other</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 2 Joint, muscle, bone - other</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 3 Joint, muscle, bone - other</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 1 Muscle Weakness (not neuro)</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 2 Muscle Weakness (not neuro)</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 1 Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 1 Cranial neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 1 Dizziness/light headedness</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 2 Dizziness/light headedness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 3 Dizziness/light headedness</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 1 Neuro - other</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 2 Neuro - other</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 1 Sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 2 Sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 3 Sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 1 Tremor</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 2 Tremor</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 1 Weakness (motor neuropathy)</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 2 Weakness (motor neuropathy)</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 3 Weakness (motor neuropathy)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 1 Anxiety/agitation</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 2 Anxiety/agitation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 1 Confusion</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 2 Confusion</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 1 Depression</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 2 Depression</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 1 Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 2 Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 1 Memory loss</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 1 Mood/consciousness change, NOS</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 1 Creatinine increase</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 2 Creatinine increase</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 1 GU - other</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 1 Cough</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 2 Cough</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 2 Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 3 Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 3 Pneumonitis/infiltrates</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 1 Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 1 Erythema/rash/eruption/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 2 Erythema/rash/eruption/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 1 Rash/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 2 Rash/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 1 Skin - other</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Grade 2 Skin - other</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bart Barlogie</name_or_title>
      <organization>UAMS Myeloma Institute</organization>
      <phone>526-6990 ext 2420</phone>
      <email>barlogiebart@uams.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

